225 related articles for article (PubMed ID: 32773025)
1. [Cell death mechanisms in non-alcoholic steatohepatitis].
Magusto J; Majdi A; Gautheron J
Biol Aujourdhui; 2020; 214(1-2):1-13. PubMed ID: 32773025
[TBL] [Abstract][Full Text] [Related]
2. Hepatic ferroptosis plays an important role as the trigger for initiating inflammation in nonalcoholic steatohepatitis.
Tsurusaki S; Tsuchiya Y; Koumura T; Nakasone M; Sakamoto T; Matsuoka M; Imai H; Yuet-Yin Kok C; Okochi H; Nakano H; Miyajima A; Tanaka M
Cell Death Dis; 2019 Jun; 10(6):449. PubMed ID: 31209199
[TBL] [Abstract][Full Text] [Related]
3. Lytic cell death in metabolic liver disease.
Gautheron J; Gores GJ; Rodrigues CMP
J Hepatol; 2020 Aug; 73(2):394-408. PubMed ID: 32298766
[TBL] [Abstract][Full Text] [Related]
4. Necroptosis contributes to non-alcoholic fatty liver disease pathoetiology with promising diagnostic and therapeutic functions.
Sun HJ; Jiao B; Wang Y; Zhang YH; Chen G; Wang ZX; Zhao H; Xie Q; Song XH
World J Gastroenterol; 2024 Apr; 30(14):1968-1981. PubMed ID: 38681120
[TBL] [Abstract][Full Text] [Related]
5. Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice.
Xu B; Jiang M; Chu Y; Wang W; Chen D; Li X; Zhang Z; Zhang D; Fan D; Nie Y; Shao F; Wu K; Liang J
J Hepatol; 2018 Apr; 68(4):773-782. PubMed ID: 29273476
[TBL] [Abstract][Full Text] [Related]
6. Nonalcoholic Steatohepatitis.
Suzuki A; Diehl AM
Annu Rev Med; 2017 Jan; 68():85-98. PubMed ID: 27732787
[TBL] [Abstract][Full Text] [Related]
7. Reduced lipoapoptosis, hedgehog pathway activation and fibrosis in caspase-2 deficient mice with non-alcoholic steatohepatitis.
Machado MV; Michelotti GA; Pereira Tde A; Boursier J; Kruger L; Swiderska-Syn M; Karaca G; Xie G; Guy CD; Bohinc B; Lindblom KR; Johnson E; Kornbluth S; Diehl AM
Gut; 2015 Jul; 64(7):1148-57. PubMed ID: 25053716
[TBL] [Abstract][Full Text] [Related]
8. Necroptosis is a key pathogenic event in human and experimental murine models of non-alcoholic steatohepatitis.
Afonso MB; Rodrigues PM; Carvalho T; Caridade M; Borralho P; Cortez-Pinto H; Castro RE; Rodrigues CM
Clin Sci (Lond); 2015 Oct; 129(8):721-39. PubMed ID: 26201023
[TBL] [Abstract][Full Text] [Related]
9. Ferroptosis Affects the Progression of Nonalcoholic Steatohepatitis via the Modulation of Lipid Peroxidation-Mediated Cell Death in Mice.
Qi J; Kim JW; Zhou Z; Lim CW; Kim B
Am J Pathol; 2020 Jan; 190(1):68-81. PubMed ID: 31610178
[TBL] [Abstract][Full Text] [Related]
10. Apoptosis and non-alcoholic fatty liver diseases.
Kanda T; Matsuoka S; Yamazaki M; Shibata T; Nirei K; Takahashi H; Kaneko T; Fujisawa M; Higuchi T; Nakamura H; Matsumoto N; Yamagami H; Ogawa M; Imazu H; Kuroda K; Moriyama M
World J Gastroenterol; 2018 Jul; 24(25):2661-2672. PubMed ID: 29991872
[TBL] [Abstract][Full Text] [Related]
11. Biochemical and molecular-genetic indicators of inflammation and apoptosis in liver cirrhosis as an outcome of the progression of non-alcoholic steatohepatitis.
Kurbatova IV; Topchieva LV; Dudanova OP; Shipovskaya AA
Ter Arkh; 2019 May; 91(4):21-27. PubMed ID: 31094472
[TBL] [Abstract][Full Text] [Related]
12. Liraglutide ameliorates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome and pyroptosis activation via mitophagy.
Yu X; Hao M; Liu Y; Ma X; Lin W; Xu Q; Zhou H; Shao N; Kuang H
Eur J Pharmacol; 2019 Dec; 864():172715. PubMed ID: 31593687
[TBL] [Abstract][Full Text] [Related]
13. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis.
Harrison SA; Goodman Z; Jabbar A; Vemulapalli R; Younes ZH; Freilich B; Sheikh MY; Schattenberg JM; Kayali Z; Zivony A; Sheikh A; Garcia-Samaniego J; Satapathy SK; Therapondos G; Mena E; Schuppan D; Robinson J; Chan JL; Hagerty DT; Sanyal AJ
J Hepatol; 2020 May; 72(5):816-827. PubMed ID: 31887369
[TBL] [Abstract][Full Text] [Related]
14. A defect in endothelial autophagy occurs in patients with non-alcoholic steatohepatitis and promotes inflammation and fibrosis.
Hammoutene A; Biquard L; Lasselin J; Kheloufi M; Tanguy M; Vion AC; Mérian J; Colnot N; Loyer X; Tedgui A; Codogno P; Lotersztajn S; Paradis V; Boulanger CM; Rautou PE
J Hepatol; 2020 Mar; 72(3):528-538. PubMed ID: 31726115
[TBL] [Abstract][Full Text] [Related]
15. Pathogenesis of NASH: How Metabolic Complications of Overnutrition Favour Lipotoxicity and Pro-Inflammatory Fatty Liver Disease.
Farrell GC; Haczeyni F; Chitturi S
Adv Exp Med Biol; 2018; 1061():19-44. PubMed ID: 29956204
[TBL] [Abstract][Full Text] [Related]
16. Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation.
Ibrahim SH; Hirsova P; Gores GJ
Gut; 2018 May; 67(5):963-972. PubMed ID: 29367207
[TBL] [Abstract][Full Text] [Related]
17. Decoding cell death signals in liver inflammation.
Brenner C; Galluzzi L; Kepp O; Kroemer G
J Hepatol; 2013 Sep; 59(3):583-94. PubMed ID: 23567086
[TBL] [Abstract][Full Text] [Related]
18. CD36 palmitoylation disrupts free fatty acid metabolism and promotes tissue inflammation in non-alcoholic steatohepatitis.
Zhao L; Zhang C; Luo X; Wang P; Zhou W; Zhong S; Xie Y; Jiang Y; Yang P; Tang R; Pan Q; Hall AR; Luong TV; Fan J; Varghese Z; Moorhead JF; Pinzani M; Chen Y; Ruan XZ
J Hepatol; 2018 Sep; 69(3):705-717. PubMed ID: 29705240
[TBL] [Abstract][Full Text] [Related]
19. Chronic Inflammation in Non-Alcoholic Steatohepatitis: Molecular Mechanisms and Therapeutic Strategies.
Luci C; Bourinet M; Leclère PS; Anty R; Gual P
Front Endocrinol (Lausanne); 2020; 11():597648. PubMed ID: 33384662
[TBL] [Abstract][Full Text] [Related]
20. CD44 is a key player in non-alcoholic steatohepatitis.
Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
